Trial 3C-14-1


A Phase 2 Clinical Trial of Nivolumab or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer

Type: Treatment
Phase: Phase II
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Chemotherapy: Systemic
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Fahim Raian, D.M., Victoria Amran, Coordinator, Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Noureddine Miloud, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Janelle Luevano, Coordinator, Angela Smith Bryant, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.